Literature DB >> 32642216

RA-ILD: does more detailed radiological classification add something to our knowledge of this condition?

Paola Faverio1, Meena Kalluri2, Fabrizio Luppi1, Giovanni Ferrara2,3.   

Abstract

Entities:  

Year:  2020        PMID: 32642216      PMCID: PMC7330798          DOI: 10.21037/jtd.2020.03.111

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
Historically, the main radiological pattern in patients with rheumatoid arthritis associated interstitial lung disease (RA-ILD) is the Usual Interstitial Pneumonia (UIP) followed by the nonspecific interstitial pneumonia (NSIP) (1). A UIP pattern at CT scan has also been associated with a worse prognosis (2,3). Besides a UIP radiographic pattern, other recognized predictors of mortality in RA-ILD are age, male gender, extent of fibrosis on CT scan and the severity of lung function impairment (2,3). Such clinical, radiological and physiological prognostic factors are shared across other ILDs including idiopathic pulmonary fibrosis (IPF) (4). However, recognizing a UIP pattern on a HRCT can be challenging, and the 2018 ATS/ERS/JRS/ALAT guidelines update on IPF standardized the interpretation of the radiology, with the aim to help clinicians in identifying the radiographic pattern and its prognostic implications (5). Yamakawa et al. performed a retrospective study including 96 consecutive Japanese patients diagnosed with RA-ILD, and they classified the HRCT findings in various categories [definite UIP, probable UIP, indeterminate for UIP, NSIP, organizing pneumonia (OP), NSIP + OP, and unclassifiable according to the 2018 ATS/ERS/JRS/ALAT IPF guidelines] (6). The authors explored the possible role of such patterns as predictors of prognosis. Noteworthy, an indeterminate pattern for UIP, was the most commonly reported (30%), followed by definite UIP (21%) and probable UIP (20%). Such prevalence is partially in contrast with data from Europe and North America where a radiographic UIP pattern was identified in the majority of cases (7,8). It is known that the distribution of reticulations and honeycombing in RA-ILD may occur in the middle or upper zones instead of being basal predominant (9). The modified HRCT classification used by the Yamakawa et al. study could have allowed this heterogeneity to be captured as indeterminate for UIP pattern. In addition, it is known that, in some cases, such radiological classification may be artificial since indeterminate and NSIP patterns on HRCT may return UIP at histology (10). The authors did not observe prognostic differences between the different CT patterns, however radiological honeycombing was associated with a poor prognosis, likewise also recently reported by Jacob et al. (11). These findings are of importance, also in relation to recent randomized controlled trials with anti-fibrotics: whilst the overall efficacy of nintedanib in slowing down the progression of the fibrosing process in the lung was proved in the whole cohort of patients, a sub-analysis of the results showed that pulmonary function was preserved by the drug mostly in those in the treatment arm with a classic UIP pattern (with honeycombing) compared to the controls in the placebo group (12). Another important clinical issue, only marginally considered so far, is the occurrence of acute exacerbations (AEs) of the disease. The authors found that these acute events influenced patients’ outcome regardless of the CT pattern. The concept of AE was originally created for IPF and subsequently extrapolated to other ILDs. AE of ILD is defined as an acute worsening of dyspnea with new ground glass opacities or consolidations on chest imaging and no evidence of other causes of acute respiratory failure including pulmonary embolism, congestive heart failure, infections and pneumothorax (13). In 2016, this definition was modified to include those acute deteriorations with known etiologies, including pulmonary infections, in the context of AE-IPF. However this modification has not yet been extended to other ILDs (14). In RA-ILD the yearly incidence of AEs is between 2.58 and 11%. The risk factors for AE are similar to the prognostic factors for mortality and include advanced age, UIP pattern and performing a surgical lung biopsy. RA disease activity outside the chest does not appear to increase risk of AE (1). Mortality for AE of RA-ILD is estimated to be similar to AE-IPF (15). Considering the high mortality associated with these acute events, it is not surprising that they negatively impact disease trajectory and prognosis. An AE was the cause of death in 22% of cases in the cohort described by Yamakawa et al., particularly in patients with an UIP and NSIP/UIP pattern. Despite its fundamental role in the natural history of disease, there is still much to know about AE pathogenesis and risk factors, in particular more studies are needed to characterize AE of CTD-ILDs since the majority of literature is focused on AE of IPF. Furthermore, health related quality of life (HrQoL) and the burden of symptoms are clinically relevant domains that are still poorly explored in CTD-ILD, although their potential prognostic value was recently highlighted. Natalini et al. showed that at baseline HrQOL in RA-ILD is worse when compared to IPF (16). After adjusting for age and pulmonary function impairment in this study, dyspnea and fatigue were predictive of poor HrQoL. A recent study found an association between overall survival and HrQoL in IPF (17). It is possible that the same associations exist in RA-ILD and other CTD-ILD, and this should be explored in future studies. In conclusion, according to the results presented by Yamakawa et al. and to the data already reported in the literature, the presence of honeycombing and the radiological extent of the pulmonary involvement are the two variables most closely associated with a poor prognosis (). UIP pattern seems to be associated to higher mortality in RA-ILD compared to other patterns; however not all studies are unanimous, especially after correcting for lung function impairment and type of treatment (1,3).
Figure 1

Predictive factors of mortality in Rheumatoid Arthritis-Interstitial Lung Disease (RA-ILD).

Predictive factors of mortality in Rheumatoid Arthritis-Interstitial Lung Disease (RA-ILD). Well-designed, prospective studies including clinical and functional data such as advanced age, gender, smoking status, pulmonary function testing, history of AEs and HrQoL will be of paramount importance in understanding the trajectory and prognosis of the disease, . The article’s supplementary files as
  17 in total

1.  Impact of the pattern of interstitial lung disease on mortality in rheumatoid arthritis: A systematic literature review and meta-analysis.

Authors:  Namrata Singh; Jimmy Varghese; Bryant R England; Joshua J Solomon; Kaleb Michaud; Ted R Mikuls; Heather S Healy; Emily M Kimpston; Marin L Schweizer
Journal:  Semin Arthritis Rheum       Date:  2019-05-15       Impact factor: 5.532

2.  Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis.

Authors:  B A Rajasekaran; D Shovlin; P Lord; C A Kelly
Journal:  Rheumatology (Oxford)       Date:  2001-09       Impact factor: 7.580

Review 3.  Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.

Authors:  Harold R Collard; Christopher J Ryerson; Tamera J Corte; Gisli Jenkins; Yasuhiro Kondoh; David J Lederer; Joyce S Lee; Toby M Maher; Athol U Wells; Katerina M Antoniou; Juergen Behr; Kevin K Brown; Vincent Cottin; Kevin R Flaherty; Junya Fukuoka; David M Hansell; Takeshi Johkoh; Naftali Kaminski; Dong Soon Kim; Martin Kolb; David A Lynch; Jeffrey L Myers; Ganesh Raghu; Luca Richeldi; Hiroyuki Taniguchi; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2016-08-01       Impact factor: 21.405

4.  MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.

Authors:  Pierre-Antoine Juge; Joyce S Lee; Esther Ebstein; Hiroshi Furukawa; Evgenia Dobrinskikh; Steven Gazal; Caroline Kannengiesser; Sébastien Ottaviani; Shomi Oka; Shigeto Tohma; Naoyuki Tsuchiya; Jorge Rojas-Serrano; Montserrat I González-Pérez; Mayra Mejía; Ivette Buendía-Roldán; Ramcés Falfán-Valencia; Enrique Ambrocio-Ortiz; Effrosyni Manali; Spyros A Papiris; Theofanis Karageorgas; Dimitrios Boumpas; Katarina Antoniou; Coline H M van Moorsel; Joanne van der Vis; Yaël A de Man; Jan C Grutters; Yaping Wang; Raphaël Borie; Lidwine Wemeau-Stervinou; Benoît Wallaert; René-Marc Flipo; Hilario Nunes; Dominique Valeyre; Nathalie Saidenberg-Kermanac'h; Marie-Christophe Boissier; Sylvain Marchand-Adam; Aline Frazier; Pascal Richette; Yannick Allanore; Jean Sibilia; Claire Dromer; Christophe Richez; Thierry Schaeverbeke; Huguette Lioté; Gabriel Thabut; Nadia Nathan; Serge Amselem; Martin Soubrier; Vincent Cottin; Annick Clément; Kevin Deane; Avram D Walts; Tasha Fingerlin; Aryeh Fischer; Jay H Ryu; Eric L Matteson; Timothy B Niewold; Deborah Assayag; Andrew Gross; Paul Wolters; Marvin I Schwarz; Michael Holers; Joshua J Solomon; Tracy Doyle; Ivan O Rosas; Cornelis Blauwendraat; Mike A Nalls; Marie-Pierre Debray; Catherine Boileau; Bruno Crestani; David A Schwartz; Philippe Dieudé
Journal:  N Engl J Med       Date:  2018-10-20       Impact factor: 91.245

5.  Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease.

Authors:  Joshua J Solomon; Jonathan H Chung; Gregory P Cosgrove; M Kristen Demoruelle; Evans R Fernandez-Perez; Aryeh Fischer; Stephen K Frankel; Stephen B Hobbs; Tristan J Huie; Jill Ketzer; Amar Mannina; Amy L Olson; Gloria Russell; Yutaka Tsuchiya; Zulma X Yunt; Pearlanne T Zelarney; Kevin K Brown; Jeffrey J Swigris
Journal:  Eur Respir J       Date:  2015-11-19       Impact factor: 16.671

6.  Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria.

Authors:  Hideaki Yamakawa; Shintaro Sato; Emiri Tsumiyama; Tomotaka Nishizawa; Rie Kawabe; Tomohiro Oba; Teppei Kamikawa; Masanobu Horikoshi; Keiichi Akasaka; Masako Amano; Kazuyoshi Kuwano; Hidekazu Matsushima
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

7.  The St. George's Respiratory Questionnaire as a prognostic factor in IPF.

Authors:  Taiki Furukawa; Hiroyuki Taniguchi; Masahiko Ando; Yasuhiro Kondoh; Kensuke Kataoka; Osamu Nishiyama; Takeshi Johkoh; Junya Fukuoka; Koji Sakamoto; Yoshinori Hasegawa
Journal:  Respir Res       Date:  2017-01-17

8.  The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis.

Authors:  Tanja Tran; Martina Šterclová; Nesrin Mogulkoc; Katarzyna Lewandowska; Veronika Müller; Marta Hájková; Mordechai R Kramer; Dragana Jovanović; Jasna Tekavec-Trkanjec; Michael Studnicka; Natalia Stoeva; Karel Hejduk; Ladislav Dušek; Samy Suissa; Martina Vašáková
Journal:  Respir Res       Date:  2020-01-08

9.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

10.  Predicting outcomes in rheumatoid arthritis related interstitial lung disease.

Authors:  Joseph Jacob; Nikhil Hirani; Coline H M van Moorsel; Srinivasan Rajagopalan; John T Murchison; Hendrik W van Es; Brian J Bartholmai; Frouke T van Beek; Marjolijn H L Struik; Gareth A Stewart; Maria Kokosi; Ryoko Egashira; Anne Laure Brun; Gary Cross; Joseph Barnett; Anand Devaraj; George Margaritopoulos; Ronald Karwoski; Elisabetta Renzoni; Toby M Maher; Athol U Wells
Journal:  Eur Respir J       Date:  2019-01-03       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.